Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Mod Pathol

Retrieve available abstracts of 16 articles:
HTML format
Text format



Single Articles


    January 2018
  1. GRIGNON DJ
    Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens.
    Mod Pathol. 2018;31.
    PubMed     Text format     Abstract available


  2. EVANS AJ
    Treatment effects in prostate cancer.
    Mod Pathol. 2018;31.
    PubMed     Text format     Abstract available


  3. RUBIN MA, Demichelis F
    The Genomics of Prostate Cancer: emerging understanding with technologic advances.
    Mod Pathol. 2018;31.
    PubMed     Text format     Abstract available


  4. KRISTIANSEN G
    Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.
    Mod Pathol. 2018;31.
    PubMed     Text format     Abstract available


  5. MAGI-GALLUZZI C
    Prostate cancer: diagnostic criteria and role of immunohistochemistry.
    Mod Pathol. 2018;31.
    PubMed     Text format     Abstract available


  6. EPSTEIN JI
    Prostate cancer grading: a decade after the 2005 modified system.
    Mod Pathol. 2018;31.
    PubMed     Text format     Abstract available


    October 2017
  7. LI H, Wang Z, Xiao W, Yan L, et al
    Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.
    Mod Pathol. 2017 Oct 27. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    May 2017
  8. KWELDAM CF, Kummerlin IP, Nieboer D, Steyerberg EW, et al
    Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
    Mod Pathol. 2017 May 19. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    August 2016
  9. LAHDENSUO K, Erickson A, Saarinen I, Seikkula H, et al
    Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Mod Pathol. 2016 Aug 26. doi: 10.1038/modpathol.2016.
    PubMed     Text format     Abstract available


    May 2016
  10. LOTAN TL, Wei W, Ludkovski O, Morais CL, et al
    Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
    Mod Pathol. 2016 May 13. doi: 10.1038/modpathol.2016.
    PubMed     Text format     Abstract available


    April 2016
  11. TROCK BJ, Fedor H, Gurel B, Jenkins RB, et al
    PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
    Mod Pathol. 2016 Apr 15. doi: 10.1038/modpathol.2016.
    PubMed     Text format     Abstract available


    March 2016
  12. KWELDAM CF, Kummerlin IP, Nieboer D, Verhoef EI, et al
    Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
    Mod Pathol. 2016 Mar 4. doi: 10.1038/modpathol.2016.
    PubMed     Text format     Abstract available


    January 2016
  13. KATO M, Tsuzuki T, Kimura K, Hirakawa A, et al
    The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.
    Mod Pathol. 2016 Jan 8. doi: 10.1038/modpathol.2015.
    PubMed     Text format     Abstract available


  14. FONTUGNE J, Davis K, Palanisamy N, Udager A, et al
    Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Mod Pathol. 2016 Jan 8. doi: 10.1038/modpathol.2015.
    PubMed     Text format     Abstract available


    November 2015
  15. MURPHY SJ, Karnes RJ, Kosari F, Castellar BE, et al
    Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
    Mod Pathol. 2015 Nov 27. doi: 10.1038/modpathol.2015.
    PubMed     Text format     Abstract available


    March 2015
  16. TAN HL, Haffner MC, Esopi DM, Vaghasia AM, et al
    Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.
    Mod Pathol. 2015;28:446-56.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: